Relcovaptan

Relcovaptan

Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis,[2] although it is not yet approved for clinical use.

References